Published

08 Dec 25

Updated

07 Aug 26

Views

Not Invested

LiquidiaLQDA

Fair Value

US$130

Share price07 Aug

US$65.3149.8% undervalued

1Y143.95%

7D-4.89%

Treprostinil Platform Expansion Into Lung Diseases Will Drive Powerful Long Term Upside

AnalystHighTarget

Analyst High Target compiles bullish analysts opinions to create narratives which represent one standard deviation above the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls

Published

08 Dec 25

Updated

07 Aug 26

Views

Not Invested

Shared on 07 Aug 26

Fair value Increased 26%

LQDA: Future Patent Decisions Seen Driving Upside As Sentiment Turns More Positive

Wall Street is getting more upbeat on Liquidia as court developments shift expectations around whether YUTREPIA can stay on track and become a go-to treatment for certain serious lung conditions. The next round of patent decisions — plus early signs from the drug’s rollout — looks like the main swing factor for what happens next.

10 views

Shared on 10 Jul 26

Fair value Increased 54%

LQDA: Legal Outcomes Around Key Patent Will Drive Future Upside

Liquidia’s outlook shifts as analysts raise their view of the company, mainly on stronger expectations for YUTREPIA and a more hopeful read of recent court rulings. The big swing factor now is what happens next in the key patent fight, with some watching from the sidelines until there’s more clarity.

14 views

Fair Value vs Share Price

US$130

vs US$65.3149.8% undervalued

81.4%

Revenue growth

53.3%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Liquidia

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

High growth potential with excellent balance sheet.

Market capUS$6.0b

PB30.0x

Estimated Growth24.5%

Dividend YieldN/A

Full analysis

CEO & management

Roger Jeffs

CEO

3.2yrs

CEO Tenure

A biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.